---
title: "Retatrutide alters fatty-acid oxidation and insulin-resistance metabolites in obesity and T2D"
id: "pubmed-42135195"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42135195"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42135195/"
doi: "10.1210/clinem/dgag201"
published_at: "2026-10-16T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Retatrutide alters fatty-acid oxidation and insulin-resistance metabolites in obesity and T2D
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42135195
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42135195/)
- **DOI:** [10.1210/clinem/dgag201](https://doi.org/10.1210%2Fclinem%2Fdgag201)
- **Published At:** 2026-10-16T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Retatrutide was evaluated in two randomized, placebo-controlled phase 2 trials in people with obesity: one trial without type 2 diabetes (n = 282, 36 weeks) and one with T2D (n = 213, 48 weeks). - Investigators performed untargeted metabolomics and lipidomics on fasting plasma samples as a post hoc exploratory analysis. - Treatment arms included multiple dose levels of **retatrutide** (obesity: 1, 4, 8, 12 mg; T2D: 0.5, 4, 8, 12 mg), placebo, and a dulaglutide 1.5 mg arm in the T2D trial. - Higher **retatrutide** doses correlated with coordinated changes in a metabolite cluster: **3-hydroxybutyrate**, acetylcarnitine, free **carnitine**, and long-chain acylcarnitines, consistent with altered fatty-acid oxidation. - Mediation analysis indicated that changes in this carnitine/ketone cluster explained 23.2% of weight reduction in participants without T2D and 12.7% in participants with T2D. - Retatrutide was also associated with reductions in metabolites linked to insulin resistance: branched-chain amino acids and catabolic products, 2-aminoadipic acid, 2-hydroxybutyrate, urate, and **triglycerides** enriched in short-chain and saturated acyl chains. - These metabolite and lipid shifts were dose-responsive, sustained through study endpoints, and observed across both trial populations. - The authors framed these changes as moving metabolic profiles in a direction associated with improved metabolic health and lower cardiovascular risk. - The analysis was post hoc and exploratory; the source did not report mechanistic dosing regimens beyond listed doses, nor did it provide longer-term clinical outcome data in this report.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42135195/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42135195%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42135195/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42135195/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42135195/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42135195/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42135195/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42135195/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42135195%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42135195%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42135195/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42135195/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42135195/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42135195/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--academic.oup.com-images-oup_pubmed_free.png) Silverchair Information Systems ](https://academic.oup.com/jcem/article-lookup/doi/10.1210/clinem/dgag201 "See full text options at Silverchair Information Systems") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42135195/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42135195/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42135195/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42135195/#abstract) * [ Figures ](https://pubmed.ncbi.nlm.nih.gov/42135195/#figures) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42135195/#similar) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42135195/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42135195/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42135195/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42135195/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42135195/#related-links) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42135195/#grants) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42135195/#linkout) Title & authors Abstract Figures Similar articles References Publication types MeSH terms Substances Related information Grants and funding LinkOut - more resources Clinical Trial J Clin Endocrinol Metab Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Clin+Endocrinol+Metab%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Clin+Endocrinol+Metab%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42135195/) . 2026 Oct 16;111(11):3217-3228. doi: 10.1210/clinem/dgag201. # Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes [Mackenzie J Pearson](https://pubmed.ncbi.nlm.nih.gov/?term=Pearson+MJ&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Jill A Willency](https://pubmed.ncbi.nlm.nih.gov/?term=Willency+JA&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Yanzhu Lin](https://pubmed.ncbi.nlm.nih.gov/?term=Lin+Y&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Arkan Abadi](https://pubmed.ncbi.nlm.nih.gov/?term=Abadi+A&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Mark L Hartman](https://pubmed.ncbi.nlm.nih.gov/?term=Hartman+ML&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Tamer Coskun](https://pubmed.ncbi.nlm.nih.gov/?term=Coskun+T&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Giacomo Ruotolo](https://pubmed.ncbi.nlm.nih.gov/?term=Ruotolo+G&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Kevin L Duffin](https://pubmed.ncbi.nlm.nih.gov/?term=Duffin+KL&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Axel Haupt](https://pubmed.ncbi.nlm.nih.gov/?term=Haupt+A&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Christopher B Newgard](https://pubmed.ncbi.nlm.nih.gov/?term=Newgard+CB&cauthor_id=42135195)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-2 "Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine, Durham, NC 27705, USA.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-3 "Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC 27705, USA.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-4 "Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27705, USA."), [Valentina Pirro](https://pubmed.ncbi.nlm.nih.gov/?term=Pirro+V&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#full-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA.") Affiliations Expand ### Affiliations * 1 Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA. * 2 Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine, Durham, NC 27705, USA. * 3 Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC 27705, USA. * 4 Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27705, USA. * PMID: **42135195** * PMCID: [ PMC13671771 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671771/) * DOI: [ 10.1210/clinem/dgag201 ](https://doi.org/10.1210/clinem/dgag201) Item in Clipboard Clinical Trial # Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes Mackenzie J Pearson et al. J Clin Endocrinol Metab. 2026. Show details Display options Display options Format Abstract PubMed PMID J Clin Endocrinol Metab Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Clin+Endocrinol+Metab%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Clin+Endocrinol+Metab%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42135195/) . 2026 Oct 16;111(11):3217-3228. doi: 10.1210/clinem/dgag201. ### Authors [Mackenzie J Pearson](https://pubmed.ncbi.nlm.nih.gov/?term=Pearson+MJ&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Jill A Willency](https://pubmed.ncbi.nlm.nih.gov/?term=Willency+JA&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Yanzhu Lin](https://pubmed.ncbi.nlm.nih.gov/?term=Lin+Y&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Arkan Abadi](https://pubmed.ncbi.nlm.nih.gov/?term=Abadi+A&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Mark L Hartman](https://pubmed.ncbi.nlm.nih.gov/?term=Hartman+ML&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Tamer Coskun](https://pubmed.ncbi.nlm.nih.gov/?term=Coskun+T&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Giacomo Ruotolo](https://pubmed.ncbi.nlm.nih.gov/?term=Ruotolo+G&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Kevin L Duffin](https://pubmed.ncbi.nlm.nih.gov/?term=Duffin+KL&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Axel Haupt](https://pubmed.ncbi.nlm.nih.gov/?term=Haupt+A&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA."), [Christopher B Newgard](https://pubmed.ncbi.nlm.nih.gov/?term=Newgard+CB&cauthor_id=42135195)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-2 "Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine, Durham, NC 27705, USA.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-3 "Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC 27705, USA.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-4 "Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27705, USA."), [Valentina Pirro](https://pubmed.ncbi.nlm.nih.gov/?term=Pirro+V&cauthor_id=42135195)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42135195/#short-view-affiliation-1 "Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA.") ### Affiliations * 1 Cardiometabolic Research, Eli Lilly and Company, Indianapolis, IN 46225, USA. * 2 Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine, Durham, NC 27705, USA. * 3 Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC 27705, USA. * 4 Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27705, USA. * PMID: **42135195** * PMCID: [ PMC13671771 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671771/) * DOI: [ 10.1210/clinem/dgag201 ](https://doi.org/10.1210/clinem/dgag201) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract **Context:** In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c and improved the lipid profiles of participants living with obesity, with and without T2D. **Objective:** Assess plasma metabolome and lipidome changes associated with retatrutide treatment. **Methods:** Metabolomics and lipidomics were performed in fasting samples from 2 randomized, placebo-controlled phase 2 trials as a post hoc exploratory analysis. Participants living with obesity with and without T2D were treated for 36 and 48 weeks, respectively. There were 282 and 213 participants in the obesity and T2D trials, respectively and the intervention(s) received were: Obesity trial: retatrutide (1, 4, 8, and 12 mg) or placebo; T2D trial: retatrutide (0.5, 4, 8, and 12 mg) or placebo or dulaglutide (1.5 mg). The main outcome measure(s) were changes in metabolite and lipid levels with retatrutide treatment against baseline levels and placebo using multiplicity correction. **Results:** At both primary and study endpoints for both populations, higher doses of retatrutide were associated with changes in a cluster of metabolites comprising 3-hydroxybutyrate, acetylcarnitine, free carnitine, and fatty acid-derived long-chain acylcarnitines. Mediation analyses suggested that changes in these biomarkers mediated 23.2% of the weight reduction response in participants without T2D and that this mediation was blunted to 12.7% in participants with T2D. Retatrutide treatment was also associated with changes in metabolites associated with insulin resistance, including branched-chain amino acids and their catabolic products, 2-aminoadipic acid, 2-hydroxybutyrate, urate, and triglycerides enriched in short-chain and saturated acyl side chains. These changes were found in both study populations and sustained across study endpoints. **Conclusion:** Retatrutide was associated with changes in 2 metabolic clusters related to fatty acid oxidation and insulin resistance in a direction associated with improved metabolic health and reduced cardiovascular risk. **Keywords:** carnitine; glucagon; ketone; lipid metabolism; multihormone receptor agonist. © The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Figures [ ![Figure 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b80e/13671771/bde0712d7997/dgag201f1.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b80e/13671771/4310111b11dc/dgag201f1.webp) ** Figure 1 ** Correlation heatmap of percent change… ** Figure 1 ** Correlation heatmap of percent change from baseline across all metabolites measured for retatrutide… **Figure 1** Correlation heatmap of percent change from baseline across all metabolites measured for retatrutide 12 mg at 24-week primary endpoint in the obesity trial population. Hierarchical clustering analysis was applied, and the returned dendrogram is displayed. Clustergram function was performed using MATLAB version 2019b (MathWorks). MetaboAnalyst 6.0 was employed for metabolite set enrichment analysis. The chemical subclasses of the clustered metabolites are highlighted as the right inset, which was edited into the figure using Adobe Photoshop 2024. [ ![Figure 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b80e/13671771/39fa33105eaa/dgag201f2.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b80e/13671771/3572503695a3/dgag201f2.webp) ** Figure 2 ** Data are from modified intention-to-treat… ** Figure 2 ** Data are from modified intention-to-treat population (obesity trial). For all treatment group and… **Figure 2** Data are from modified intention-to-treat population (obesity trial). For all treatment group and timepoints, least square mean of percent change from baseline ± standard error for (A) 3-HB (24-week percent change from baseline [FDR-adjusted _P_ -value vs placebo, _P_]: Placebo; 19.1; retatrutide 1, 4, 8, and 12 mg: 25.6 [_P_ > .05], 124.6 [_P_ .05], 62.72 [_P_ .05], 27.7 [_P_ < .001], 37.2 [_P_ < .001], and 53.3 [_P_ < .00
## Related Clinical Research

- [Sarcopenia in Aging, Obesity, and Type 2 Diabetes: Mechanisms and Interventions](https://medichelpline.com/clinical-feed/pubmed-42624776.md) (DOI: 10.1097/CM9.0000000000004152)
- [Metformin reduces metabolic and oxidative changes in a high-sucrose Drosophila model](https://medichelpline.com/clinical-feed/plos-one-13-metformin-modulates-survival-oxidative-stress-and-gene-expression-in-a-high.md)
- [Continuous Glucose Monitoring in Non-Insulin-Treated Type 2 Diabetes: A Prospective Evaluation of](https://medichelpline.com/clinical-feed/pubmed-42808545.md) (DOI: 10.18553/jmcp.2026.32.10.1215)
- [Self-Management Program Lowers HbA1c, eGFR, SBP, LDL-C in High-Risk DKD Patients with Type 2 Diabe](https://medichelpline.com/clinical-feed/plos-one-11-effectiveness-of-a-self-management-intervention-on-clinical-outcomes-among.md)
- [Endocrine Society Comments on the 2027 Medicare Physician Fee Schedule Proposed Rule](https://medichelpline.com/clinical-feed/endocrine-news-0-society-submits-comments-on-the-medicare-physician-fee-schedule-proposed-rule.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.